Company news
Oxford Nanopore Technologies Plc (LSE:ONT) news
Oxford Nanopore Technologies Plc news releases on 6ix. Latest, Aug 25, 2023: Notice of Results and Capital Markets Day
Press releases — page 3
Notice of Results and Capital Markets Day
August 25, 2023
Kate Priestman appointed as Non-Executive Director
July 13, 2023
National German rare disease study
June 12, 2023
Change of Broker
June 9, 2023
Next step of PathoQuest strategic collaboration
May 12, 2023
Director/PDMR Notification
May 4, 2023
New infectious disease partnership with bioMerieux
April 17, 2023
Oxford Nanopore and bioMérieux to Enter Into a Strategic Partnership Agreement to Develop Innovative Infectious Disease Diagnostics
April 14, 2023
NIH Alzheimers study shows scaled, accurate data
April 11, 2023
NIHR, Oxford Nanopore announce new health study
March 31, 2023
Final results for the year ended 31 December 2022
March 21, 2023
Notice of Results
March 9, 2023
Changes to Director Roles and Responsibilities
February 27, 2023
Total Voting Rights and Issue of Equity
February 1, 2023
Trading update
January 17, 2023
Issue of equity and Total Voting Rights
January 3, 2023
Interim results for the period ended 30 June 2022
September 13, 2022
Sale and leaseback of headquarters building
July 11, 2022
Duncan Tatton-Brown appointed as Non-Exec Chair
June 30, 2022
ONT releases Remora:most comprehensive methylation
May 26, 2022
Oxford Nanopore announces tech updates
May 20, 2022
ONT opens user conference, rich science programme
May 19, 2022
ONT chosen for comprehensive human genome program
May 13, 2022
Genomics England expands Nanopore use in cancer
April 4, 2022
Agreement
April 1, 2022
ONT shows new high-accuracy, high-output chemistry
March 30, 2022
Nanopore sequencing profiles TB: FIND evaluation
March 24, 2022
Oxford Nanopore releases Short Fragment Mode
March 23, 2022
Preliminary Results and Guidance Update
March 22, 2022
Publication: Nanopore IDs >50 genetic diseases
March 8, 2022
Appointment of Senior Independent Director
January 24, 2022
Fastest human genome sequence uses Oxford Nanopore
January 13, 2022
Update to FY21 revenue guidance
January 7, 2022
Company to present at JP Morgan Healthcare conf
January 7, 2022
Oxford Nanopore announces technology updates
December 2, 2021
Update to revenue guidance
November 9, 2021
PDMR Notification (ESPP) and Director Declaration
November 1, 2021
Upgrade to full-year revenue guidance
October 14, 2021
Share Incentive Plan, Director/PDMR Transactions
October 13, 2021
Exercise of Over-allotment Option
October 8, 2021
Notification of Transactions of Director/PDMR
October 8, 2021
Block Listing Application/Directorate Change
October 5, 2021
Approval and Publication of Prospectus
September 30, 2021
Announcement of Offer Price
September 30, 2021
Cancellation of admission
April 30, 2004
Rule 2.10 Announcement
March 3, 2004
Holding in Company
February 20, 2004
Re Contract
February 5, 2004
Grant of Options
January 13, 2004
Director Shareholding
January 9, 2004